宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

01541 宜明昂科-B

未开盘 11-18 16:08:08

7.310

-0.310

-4.07%

最高7.600	最低7.200	成交量606.98万
今开7.330	昨收7.620	日振幅5.25%
总市值27.35亿	流通市值25.51亿	总股本3.74亿
成交额4,494万	换手率1.74%	流通股本3.49亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"01541","market":"HK","secType":"STK","nameCN":"宜明昂科-B","latestPrice":7.31,"timestamp":1731917288013,"preClose":7.62,"halted":0,"volume":6069800,"delay":0,"floatShares":349000000,"shares":374157695,"eps":-1.1290668,"marketStatus":"未开盘","marketStatusCode":0,"change":-0.31,"latestTime":"11-18 16:08:08","open":7.33,"high":7.6,"low":7.2,"amount":44938902,"amplitude":0.052493,"askPrice":7.37,"askSize":1000,"bidPrice":7.31,"bidSize":800,"shortable":3,"etf":0,"ttmEps":-1.0868486907028703,"exchange":"SEHK","tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1731979800000},"adr":0,"listingDate":1693843200000,"adjPreClose":7.62,"openAndCloseTimeList":[[1731893400000,1731902400000],[1731906000000,1731916800000]],"volumeRatio":0.29607791443012443,"lotSize":200,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/01541","defaultTab":"news","newsList":[{"id":"2484664436","title":"宜明昂科-B(01541)：IMM0306与来那度胺联用治疗慢性淋巴瘤的临床试验结果表明突出","url":"https://stock-news.laohu8.com/highlight/detail?id=2484664436","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484664436?lang=zh_cn&edition=full","pubTime":"2024-11-18 09:56","pubTimestamp":1731895013,"startTime":"0","endTime":"0","summary":"IMM0306与来那度胺联用治疗慢性淋巴瘤的临床试验结果表明突出","market":"sh","thumbnail":"https://img.zhitongcaijing.com/image/20241118/20241118095710_67911.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250","type":0,"news_type":0,"thumbnails":["https://img.zhitongcaijing.com/image/20241118/20241118095710_67911.png?x-oss-process=image/format,jpg/quality,Q_80/resize,w_250"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212059.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1583","BK1576","BK1161","BK1141","01541","03347"],"gpt_icon":0},{"id":"2484643756","title":"宜明昂科-B(01541)下跌5.25%，报7.22元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2484643756","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484643756?lang=zh_cn&edition=full","pubTime":"2024-11-18 09:42","pubTimestamp":1731894147,"startTime":"0","endTime":"0","summary":"11月18日，宜明昂科-B(01541)盘中下跌5.25%，截至09:42，报7.22元/股，成交737.28万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司，主要致力于开发肿瘤免疫疗法，特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉，包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2024年中报，宜明昂科-B营业总收入7.7万元、净利润-1.66亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/18094245386215.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2484766520","title":"宜明昂科(01541.HK)IMM0306临床研究目前在积极招募及观察中","url":"https://stock-news.laohu8.com/highlight/detail?id=2484766520","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484766520?lang=zh_cn&edition=full","pubTime":"2024-11-18 08:23","pubTimestamp":1731889380,"startTime":"0","endTime":"0","summary":"宜明昂科公布，IMM0306与来那度胺联用治疗慢性淋巴瘤的Ib/IIa期临床试验于10月26日已合共招募27例可评估的患者。IMM0306是一种靶向分化簇47及分化簇20的双特异性分子，是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子。通过增强的抗体依赖的细胞吞噬作用和抗体依赖的细胞毒性作用，IMM0306可同时与恶性B细胞上表达的CD47和CD20结合，相较于对CD47，对CD20的亲和力更高，从而可改善治疗效果。沽空资料截至 2024-11-15 16:25。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230915102621607_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230915102621607_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1397245/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2484680236","title":"宜明昂科-B(01541)：IMM0306与来那度胺联用治疗慢性淋巴瘤的Ib/IIa期临床试验于10月26日已合共招募27例可评估的患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2484680236","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2484680236?lang=zh_cn&edition=full","pubTime":"2024-11-18 08:06","pubTimestamp":1731888374,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，IMM0306与来那度胺联用治疗慢性淋巴瘤的Ib/IIa期临床试验于2024年10月26日已合共招募27例可评估的患者。由集团独立研发的IMM0306是一种靶向分化簇47及分化簇20的双特异性分子，是全球首个进入临床阶段的CD47和CD20双靶向双特异性分子。通过增强的抗体依赖的细胞吞噬作用和抗体依赖的细胞毒性作用 ，IMM0306可同时与恶性B细胞上表达的CD47和CD20结合，相较于对CD47，对CD20的亲和力更高，从而可改善治疗效果。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1212010.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","BK1576","01541","BK1141","BK1161","03347"],"gpt_icon":0},{"id":"2483134801","title":"宜明昂科-B11月15日主力资金流出16万元 连续3日减仓","url":"https://stock-news.laohu8.com/highlight/detail?id=2483134801","media":"市场透视","labels":["Shareholding Changes"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483134801?lang=zh_cn&edition=full","pubTime":"2024-11-15 16:15","pubTimestamp":1731658540,"startTime":"0","endTime":"0","summary":"11月15日, 宜明昂科-B股价跌3.42%，报收7.62元，成交金额6693万元，换手率2.45%，振幅10.77%，量比0.42。宜明昂科-B今日主力资金净流出16万元，连续3日净流出，上一交易日主力净流出124万元，今日环比减少87.10%。近一年数据显示，该股主力连续3日净流出后，次日下跌概率为57.14%，平均跌幅为6.02%。该股近5个交易日上涨2.01%，主力资金累计净流入594万元；近20日主力资金累计净流出2106万元，其中净流出天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115161554abc3df2c&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115161554abc3df2c&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"Shareholding Changes","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["01541","BK1161"],"gpt_icon":0},{"id":"2483364119","title":"宜明昂科-B(01541)上涨5.58%，报8.33元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483364119","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483364119?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:35","pubTimestamp":1731634521,"startTime":"0","endTime":"0","summary":"11月15日，宜明昂科-B盘中上涨5.58%，截至09:35，报8.33元/股，成交680.26万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司，主要致力于开发肿瘤免疫疗法，特别是对先天性免疫和适应性免疫进行系统性利用。截至2024年中报，宜明昂科-B营业总收入7.7万元、净利润-1.66亿元。11月13日，余治华于2024-11-13减持625.2万股，每股均价8.7205港元，最新持股数目1301万股，最新持股比例3.73%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/15093545323482.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2483367339","title":"宜明昂科-B盘中异动 急速拉升5.20%报8.300港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483367339","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483367339?lang=zh_cn&edition=full","pubTime":"2024-11-15 09:35","pubTimestamp":1731634514,"startTime":"0","endTime":"0","summary":"2024年11月15日早盘09时35分，宜明昂科-B股票出现异动，股价急速拉升5.20%。截至发稿，该股报8.300港元/股，成交量82.62万股，换手率0.24%，振幅3.93%。资金方面，该股资金流入361.501万港元，流出185.498万港元。宜明昂科-B股票所在的生物技术行业中，整体涨幅为0.09%。其相关个股中，迈博药业-B、宜明昂科-B、晶泰科技涨幅较大，振幅较大的相关个股有晶泰科技、康宁杰瑞制药-B、再鼎医药，振幅分别为9.88%、4.26%、4.05%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115093514a23922bc&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241115093514a23922bc&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2483481175","title":"宜明昂科-B(01541)下跌5.08%，报8.04元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483481175","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483481175?lang=zh_cn&edition=full","pubTime":"2024-11-14 14:16","pubTimestamp":1731564990,"startTime":"0","endTime":"0","summary":"11月14日，宜明昂科-B(01541)盘中下跌5.08%，截至14:16，报8.04元/股，成交1.02亿元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司，主要致力于开发肿瘤免疫疗法，特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉，包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2024年中报，宜明昂科-B营业总收入7.7万元、净利润-1.66亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/14141645282879.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2483895831","title":"【港股通】宜明昂科(01541)盘初一度涨超7% 开展内分泌治疗无效或复发ER+晚期乳腺癌的II期临床研究","url":"https://stock-news.laohu8.com/highlight/detail?id=2483895831","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483895831?lang=zh_cn&edition=full","pubTime":"2024-11-14 10:20","pubTimestamp":1731550810,"startTime":"0","endTime":"0","summary":"金吾财讯 | 宜明昂科(01541)盘初一度涨超7%，截至发稿，涨3.66%，报8.78港元，成交额4475万港元。消息面上，公司宣布，公司已启动IMM27M治疗内分泌疗法失败后或复发的雌激素受体阳性(ER+)晚期乳癌的II期临床试验，并已招募首例患者。此外，IMM27M I期剂量递增研究于2023年年底完成。已启动IMM27M治疗内分泌疗法失败后或复发的雌激素受体阳性(ER+)晚期乳癌的II期临床试验","market":"other","thumbnail":"https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/OTEzM2QyMzQzMjc2MzA3OTk2MA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"1947697","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01541","HSTECH","YANG","HSCEI","BK1161"],"gpt_icon":0},{"id":"2483860785","title":"港股异动 | 宜明昂科-B(01541)早盘涨超3% 已启动IMM27M II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2483860785","media":"智通财经","labels":["movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483860785?lang=zh_cn&edition=full","pubTime":"2024-11-14 09:34","pubTimestamp":1731548059,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B早盘涨超3%，截至发稿，涨3.31%，报8.75港元，成交额490.34万港元。消息面上，宜明昂科-B公告，公司已启动IMM27M治疗内分泌疗法失败后或复发的雌激素受体阳性(ER+)晚期乳癌的II期临床试验，并已招募首例患者。此外，IMM27M I期剂量递增研究于2023年年底完成，显示的结果如下：于I期试验，合共招募八例可评估的ER+晚期或转移性乳腺癌患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210712.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK1576","01541","BK1141","BK1583","03347"],"gpt_icon":0},{"id":"2483020860","title":"宜明昂科-B盘中异动 急速拉升5.08%","url":"https://stock-news.laohu8.com/highlight/detail?id=2483020860","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483020860?lang=zh_cn&edition=full","pubTime":"2024-11-14 09:34","pubTimestamp":1731548045,"startTime":"0","endTime":"0","summary":"2024年11月14日早盘09时34分，宜明昂科-B股票出现波动，股价大幅拉升5.08%。截至发稿，该股报8.900港元/股，成交量78.78万股，换手率0.23%，振幅3.54%。宜明昂科-B股票所在的生物技术行业中，整体跌幅为0.24%。其相关个股中，晶泰科技、迈博药业-B、宜明昂科-B涨幅较大，振幅较大的相关个股有晶泰科技、康宁杰瑞制药-B、宜明昂科-B，振幅分别为7.61%、4.89%、3.54%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114093405971a66c8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241114093405971a66c8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2483071068","title":"宜明昂科-B(01541)：IMM27M临床试验更新","url":"https://stock-news.laohu8.com/highlight/detail?id=2483071068","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483071068?lang=zh_cn&edition=full","pubTime":"2024-11-13 18:16","pubTimestamp":1731493003,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宜明昂科-B 发布公告，公司已启动IMM27M治疗内分泌疗法失败后或复发的雌激素受体阳性(ER+)晚期乳癌的II期临床试验，并已招募首例患者。此外，IMM27MI期剂量递增研究于2023年年底完成，显示的结果如下：于I期试验，合共招募八例可评估的ER+晚期或转移性乳腺癌患者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210477.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1141","BK1576","01541","BK1161","BK1583"],"gpt_icon":0},{"id":"2483071693","title":"宜明昂科(01541.HK)已启动IMM27M II期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2483071693","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483071693?lang=zh_cn&edition=full","pubTime":"2024-11-13 18:03","pubTimestamp":1731492180,"startTime":"0","endTime":"0","summary":"宜明昂科公布，公司已启动IMM27M治疗内分泌疗法失败后或复发的雌激素受体阳性(ER+)晚期乳癌的II期临床试验，并已招募首例患者。此外，IMM27M I期剂量递增研究于2023年年底完成。显示结果中，于I期试验，合共招募八例可评估的ER+晚期或转移性乳腺癌患者。其中，两例达到部分缓解及四例患者病情稳定，总体缓解率达25%及疾病控制率达75%；显示积极的疗效信号；及IMM27M安全并具有良好的耐受性，于I期探索的最高剂量7.5 mg/kg并无观察到剂量限制性毒性。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230915102621607_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230915102621607_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1396385/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1576","BK1141","03347","BK1161","BK1583","01541"],"gpt_icon":0},{"id":"2483094177","title":"宜明昂科-B高开逾4% 核心产品IMM01 III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2483094177","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483094177?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:34","pubTimestamp":1731461691,"startTime":"0","endTime":"0","summary":"宜明昂科-B（01541）早盘高开逾4%，截至发稿，股价上涨2.58%，现报9.55港元，成交额3026.22万港元。\n　　宜明昂科公告，集团核心产品IMM01（替达派西普）联合阿扎胞苷进行慢性粒-单核细胞白血病（CMML）一线治疗的III期临床试验成功完成首例患者给药。这是全球首个分化簇47 （CD47）靶向药物针对CMML一线治疗的注册III期临床研究。\n\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"highlight_sina","url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-13/doc-incvwrzw2536025.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}","selectors":".art_box, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action, .fl_popup, .weibo_info","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2024-11-13/doc-incvwrzw2536025.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_sina","symbols":["BK1583","BK1161","BK1141","03347","01541","BK1576"],"gpt_icon":0},{"id":"2483094255","title":"宜明昂科-B(01541)上涨8.7%，报10.12元/股","url":"https://stock-news.laohu8.com/highlight/detail?id=2483094255","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483094255?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:30","pubTimestamp":1731461415,"startTime":"0","endTime":"0","summary":"11月13日，宜明昂科-B(01541)盘中上涨8.7%，截至09:30，报10.12元/股，成交504.6万元。宜明昂科生物医药技术(上海)股份有限公司是一家以科研为导向的生物技术公司，主要致力于开发肿瘤免疫疗法，特别是对先天性免疫和适应性免疫进行系统性利用。该公司曾获得多项荣誉，包括“第二届生物科技创新50企业榜单”、“药物创新济世奖”、“2021中国医药创新种子企业100强”等。截至2024年中报，宜明昂科-B营业总收入7.7万元、净利润-1.66亿元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://hk.jrj.com.cn/2024/11/13093045229307.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2483009246","title":"宜明昂科-B盘中异动 早盘大幅拉升5.26%报9.800港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2483009246","media":"市场透视","labels":["Business Data"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483009246?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:30","pubTimestamp":1731461409,"startTime":"0","endTime":"0","summary":"2024年11月13日早盘09时30分，宜明昂科-B股票出现波动，股价急速上涨5.26%。截至发稿，该股报9.800港元/股，成交量44.94万股，换手率0.13%，振幅2.90%。资金方面，该股资金流入78.3546万港元，流出10.192万港元。宜明昂科-B股票所在的生物技术行业中，整体跌幅为0.79%。其相关个股中，宜明昂科-B、君实生物、乐普生物-B涨幅较大，振幅较大的相关个股有宜明昂科-B、基石药业-B、再鼎医药，振幅分别为2.90%、2.60%、2.25%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093009abbb7dbf&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241113093009abbb7dbf&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Business Data","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","01541"],"gpt_icon":0},{"id":"2483943080","title":"港股异动 | 宜明昂科-B(01541)高开逾4% 核心产品IMM01 III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2483943080","media":"智通财经","labels":["Product Release","movement"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483943080?lang=zh_cn&edition=full","pubTime":"2024-11-13 09:23","pubTimestamp":1731461000,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，宜明昂科-B高开逾4%，截至发稿，涨4.19%，报9.7港元，成交额345.51万港元。消息面上，宜明昂科公告，集团核心产品IMM01联合阿扎胞苷进行慢性粒-单核细胞白血病一线治疗的III期临床试验成功完成首例患者给药。这是全球首个分化簇47 靶向药物针对CMML一线治疗的注册III期临床研究。此外，宜明昂科上月底公告，IMM0306治疗系统性红斑狼疮的Ib期临床试验成功完成首例患者给药。截至本公告日期，集团拥有IMM0306的全球知识产权及商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210185.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"Product Release,movement","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["03347","BK1141","BK1576","01541","BK1161","BK1583","BK4134","III"],"gpt_icon":0},{"id":"2483806700","title":"智通港股早知道 | 香港将促进大湾区内跨境低空飞行活动 2025年起节假日增加2天","url":"https://stock-news.laohu8.com/highlight/detail?id=2483806700","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483806700?lang=zh_cn&edition=full","pubTime":"2024-11-13 07:43","pubTimestamp":1731455006,"startTime":"0","endTime":"0","summary":"香港将促进大湾区内的跨境低空飞行活动香港新一份施政报告宣布成立“发展低空经济工作组”，香港特区政府财政司副司长黄伟纶今日以组长身份召开工作组的首次会议。一是全体公民放假的假日增加2天，即农历除夕、5月2日，增加后春节放假4天，劳动节放假2天。除个别特殊情形外，法定节假日假期前后连续工作一般不超过6天。本集团拥有IMM1的全球知识产权及商业化权利。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1210159.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1587","LU0315179316.USD","BK1161","LU0588546209.SGD","00780","BK1164","BK1170","SG9999006597.SGD","SG9999001069.SGD","LU1969619763.USD","BK1104","YANG","09626","HSTECH","LU1115378108.SGD","SGXZ90724238.SGD","BK1583","SG9999001051.SGD","01541","LU2097828714.EUR","SG9999001226.SGD","LU2097828557.USD","LU2097828805.USD","BK1508","159983","SG9999001093.SGD","BK1588","SG9999003461.SGD","BK1604","HSCEI","BK1575","BK1516","BK1095","BK1608","LU0278937759.USD","BK1500","LU0640798160.USD","LU2097828474.EUR","LU2328871848.SGD","06160","06088","LU2097828631.EUR","LU0307460666.USD","IE0034224299.USD","LU2460026573.USD"],"gpt_icon":1},{"id":"2483039984","title":"宜明昂科(01541.HK)核心产品IMM01 III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2483039984","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2483039984?lang=zh_cn&edition=full","pubTime":"2024-11-13 01:18","pubTimestamp":1731431880,"startTime":"0","endTime":"0","summary":"宜明昂科－Ｂ(01541.HK) 公布，集团核心产品IMM01(替达派西普)联合阿扎胞苷进行慢性粒-单核细胞白血病(CMML)一线治疗的III期临床试验成功完成首例患者给药。这是全球首个分化簇47 (CD47)靶向药物针对CMML一线治疗的注册III期临床研究。(de/d)(港股报价延迟最少十五分钟。沽空资料截至 2024-11-12 16:25。)AASTOCKS新闻","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20230915102623267_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20230915102623267_s.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1396079/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1141","BK1583","BK1161","01541","03347","BK1576"],"gpt_icon":0},{"id":"2482930708","title":"宜明昂科-B：IMM01(替达派西普)联合阿扎胞苷进行CMML一线治疗的III期临床试验完成首例患者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2482930708","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2482930708?lang=zh_cn&edition=full","pubTime":"2024-11-12 18:59","pubTimestamp":1731409196,"startTime":"0","endTime":"0","summary":"格隆汇11月12日丨宜明昂科-B公告，董事会欣然宣布，IMM01联合阿扎胞苷进行慢性粒-单核细胞白血病一线治疗的III期临床试验成功完成首例患者给药。这是全球首个分化簇47靶向药物针对CMML一线治疗的注册III期临床研究。此外，IMM01的CD47结合结构域经过特别改造能够避免与人体红细胞结合。凭藉差异化的分子设计，IMM01表现出良好的安全性并证实其激活巨噬细胞的能力。集团拥有IMM01的全球知识产权及商业化权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112190225abb9d191&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20241112190225abb9d191&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["03347","BK1576","01541","BK1141","BK1583","BK1161"],"gpt_icon":0}],"profile":{"websiteUrl":"http://immuneonco.com","stockEarnings":[{"period":"1week","weight":-0.0908},{"period":"1month","weight":0.2892},{"period":"3month","weight":-0.1851},{"period":"6month","weight":-0.4945},{"period":"1year","weight":-0.7385},{"period":"ytd","weight":-0.7555}],"compareEarnings":[{"period":"1week","weight":-0.0416},{"period":"1month","weight":-0.059},{"period":"3month","weight":0.118},{"period":"6month","weight":0.0198},{"period":"1year","weight":0.1216},{"period":"ytd","weight":0.1484}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"宜明昂科生物医药技术（上海）股份有限公司是一家主要从事测试生物技术研发的中国公司。该公司的主要业务包括开发用于系统利用先天性和适应性免疫的生物技术，以及开发下一代肿瘤免疫疗法，免疫疗法主要专注于适应性免疫系统。该公司主要在中国国内和海外市场开展业务。","exchange":"SEHK","name":"宜明昂科-B","nameEN":"IMMUNEONCO-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.29.1","shortVersion":"4.29.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"宜明昂科-B,01541,宜明昂科-B股票,宜明昂科-B股票老虎,宜明昂科-B股票老虎国际,宜明昂科-B行情,宜明昂科-B股票行情,宜明昂科-B股价,宜明昂科-B股市,宜明昂科-B股票价格,宜明昂科-B股票交易,宜明昂科-B股票购买,宜明昂科-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"宜明昂科-B(01541)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供宜明昂科-B(01541)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}